21 May 2009
Potential living donor disqualification due to immunological factors
K Michalska, D Lewandowska, J Gozdowska, A Jałbrzykowska, I Sobierajska, M Durlik, M NowaczykAnn Transplant 2009; 14(1): 69-69 :: ID: 880454
Abstract
Background: The objective of the study was to analyze retrospectively immunological factors as the reason for potential living kidney donor disqualification.
Material/Methods: Between 1995-2008, 340 individuals who volunteered to
donate kidney to a related recipient were evaluated at our centre. In potential donors, CDC tests with a potential recipient was performed. In cases, in which the recipient was awaiting a consecutive transplantation and the result of his cross-match with a potential donor was negative, HLA antigen expression was examined in the donor to exclude any HLA incompatibilities with the potential donor.
Results: Of 340 living kidney donor candidates, 206 individuals (61.5%) were
disqualified. Of these, 31 individuals (27%) were disqualified due to immunological reasons. In 23 individuals, the reason for disqualification was positive or doubtfully false result of the CDC test with the recipient. 3 individuals were disqualified in spite of the negative result of the cross-match due to the repetition of incompatibility, that is due to having the same HLA antigens that were found in the previous donor and were not present in the recipient. In 6 cases, the reason for disqualification was blood group incompatibility or a complete lack of HLA antigen compatibility (currently it is not an absolute contraindication).
Conclusions: Our results show that immunological factors constitute an important problem when selecting a living donor, especially for patients awaiting consecutive transplantations and immunized patients, even those in whom low titers of antibodies are found. In some cases, an advanced clinical examination of the donor should be preceded by an extended panel of immunological tests.
Keywords: Living Donor
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






